Favorable Japan Environment Nurtures Daiichi/CTL Cell Therapy Deal
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo's recent deal for Japan rights to a cell therapy agent illustrates the ongoing corporate appetite for assets able to benefit from the country's favorable regulatory framework for such products.
You may also be interested in...
Asia Deal Watch: CANbridge Licenses Orphan Disease Candidates From Mirum, LogicBio
US-based, China-focused CANbridge moves into cholestatic liver disease and enzyme replacement therapy via two deals. Plus deals involving LegoChem, TransThera, Morepen, Daiichi Sankyo, Geneseeq, Innocare, Biosplice, Sirnaomics and Walvax.
Quick Listen: Scrip’s Five Must-Know Things
In this week's podcast version of Five Must-Know Things, hear about possible new life for Tecfidera, activist investors and GSK, a new mRNA vaccine in Europe, diversity in clinical trials, and a look at last year’s drug launches.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.